323 related articles for article (PubMed ID: 31801386)
21. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.
Kimura E; Han JJ; Li S; Fall B; Ra J; Haraguchi M; Tapscott SJ; Chamberlain JS
Hum Mol Genet; 2008 Aug; 17(16):2507-17. PubMed ID: 18511457
[TBL] [Abstract][Full Text] [Related]
22. Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene.
Moisset PA; Skuk D; Asselin I; Goulet M; Roy B; Karpati G; Tremblay JP
Biochem Biophys Res Commun; 1998 Jun; 247(1):94-9. PubMed ID: 9636661
[TBL] [Abstract][Full Text] [Related]
23. In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin.
Danilov KA; Vassilieva SG; Polikarpova AV; Starikova AV; Shmidt AA; Galkin II; Tsitrina AA; Egorova TV; Orlov SN; Kotelevtsev YV
Exp Cell Res; 2020 Jul; 392(2):112033. PubMed ID: 32360435
[TBL] [Abstract][Full Text] [Related]
24. Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.
Lala-Tabbert N; Fu D; Wiper-Bergeron N
Stem Cells Transl Med; 2016 Apr; 5(4):500-10. PubMed ID: 26941360
[TBL] [Abstract][Full Text] [Related]
25. Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy.
He R; Li H; Wang L; Li Y; Zhang Y; Chen M; Zhu Y; Zhang C
Biol Res; 2020 May; 53(1):22. PubMed ID: 32430065
[TBL] [Abstract][Full Text] [Related]
26. Lentiviral vectors can be used for full-length dystrophin gene therapy.
Counsell JR; Asgarian Z; Meng J; Ferrer V; Vink CA; Howe SJ; Waddington SN; Thrasher AJ; Muntoni F; Morgan JE; Danos O
Sci Rep; 2017 Mar; 7(1):79. PubMed ID: 28250438
[TBL] [Abstract][Full Text] [Related]
27. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
[TBL] [Abstract][Full Text] [Related]
28. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
[TBL] [Abstract][Full Text] [Related]
29. Effect of injecting primary myoblasts versus putative muscle-derived stem cells on mass and force generation in mdx mice.
Mueller GM; O'Day T; Watchko JF; Ontell M
Hum Gene Ther; 2002 Jun; 13(9):1081-90. PubMed ID: 12067441
[TBL] [Abstract][Full Text] [Related]
30. Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models.
Quenneville SP; Chapdelaine P; Skuk D; Paradis M; Goulet M; Rousseau J; Xiao X; Garcia L; Tremblay JP
Mol Ther; 2007 Feb; 15(2):431-8. PubMed ID: 17235323
[TBL] [Abstract][Full Text] [Related]
31. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
Koo T; Popplewell L; Athanasopoulos T; Dickson G
Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
[TBL] [Abstract][Full Text] [Related]
32. Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells.
Meng J; Counsell J; Morgan JE
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998454
[TBL] [Abstract][Full Text] [Related]
33. Sertoli Cells Improve Myogenic Differentiation, Reduce Fibrogenic Markers, and Induce Utrophin Expression in Human DMD Myoblasts.
Salvadori L; Chiappalupi S; Arato I; Mancuso F; Calvitti M; Marchetti MC; Riuzzi F; Calafiore R; Luca G; Sorci G
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680138
[TBL] [Abstract][Full Text] [Related]
34. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
[TBL] [Abstract][Full Text] [Related]
35. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
36. Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal.
Benabdallah BF; Bouchentouf M; Tremblay JP
Transplantation; 2005 Jun; 79(12):1696-702. PubMed ID: 15973171
[TBL] [Abstract][Full Text] [Related]
37. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
38. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
[TBL] [Abstract][Full Text] [Related]
39. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
[TBL] [Abstract][Full Text] [Related]
40. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
